These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 15124237)

  • 1. Whither the ACR20?
    Felson DT
    J Rheumatol; 2004 May; 31(5):835-7. PubMed ID: 15124237
    [No Abstract]   [Full Text] [Related]  

  • 2. Rheumatoid arthritis treatment and monitoring of outcomes--where are we [corrected] in 2007?
    Yazici Y; Abramson SB
    Bull NYU Hosp Jt Dis; 2007; 65(4):300-5. PubMed ID: 18081549
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Measures of rheumatoid arthritis disease activity.
    Kirwan J
    J Rheumatol; 2009 Feb; 36(2):442-3; author reply 443-4. PubMed ID: 19208571
    [No Abstract]   [Full Text] [Related]  

  • 4. Defining response to disease modifying antirheumatic drugs in patients with rheumatoid arthritis.
    Hider SL; Bruce IN; Silman AJ; Symmons DP
    J Rheumatol; 2005 Jan; 32(1):6-10. PubMed ID: 15630715
    [No Abstract]   [Full Text] [Related]  

  • 5. Current world literature.
    Curr Opin Rheumatol; 2010 May; 22(3):348-61. PubMed ID: 20351495
    [No Abstract]   [Full Text] [Related]  

  • 6. Continuous indices of core data set measures in rheumatoid arthritis clinical trials: lower responses to placebo than seen with categorical responses with the American College of Rheumatology 20% criteria.
    Pincus T; Amara I; Koch GG
    Arthritis Rheum; 2005 Apr; 52(4):1031-6. PubMed ID: 15818698
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Progress toward the cure of rheumatoid arthritis? The BeSt study.
    Weisman MH
    Arthritis Rheum; 2005 Nov; 52(11):3326-32. PubMed ID: 16258928
    [No Abstract]   [Full Text] [Related]  

  • 8. Criteria for improvement in rheumatoid arthritis: alternatives to the American College of Rheumatology 20.
    Albert DA; Huang G; Dubrow G; Brensinger CM; Berlin JA; Williams HJ
    J Rheumatol; 2004 May; 31(5):856-66. PubMed ID: 15124243
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcome issues for rheumatoid arthritis: what do we have and what do we want?
    Albert DA
    J Rheumatol; 2006 Mar; 33(3):441-2. PubMed ID: 16511910
    [No Abstract]   [Full Text] [Related]  

  • 10. A perspective from India on the 2010 rheumatoid arthritis classification criteria: comment on the article by Aletaha et al.
    Chopra A
    Arthritis Rheum; 2011 Feb; 63(2):570; author reply 570-1. PubMed ID: 21280013
    [No Abstract]   [Full Text] [Related]  

  • 11. Non-overlapping American College of Rheumatology response rates: a better way to report response in rheumatoid arthritis clinical trials.
    Boers M; Kostense PJ
    Arthritis Rheum; 2010 Dec; 62(12):3524-7. PubMed ID: 20722016
    [No Abstract]   [Full Text] [Related]  

  • 12. The concept of disease modification in spondyloarthropathy.
    Marzo-Ortega H; Emery P; McGonagle D
    J Rheumatol; 2002 Aug; 29(8):1583-5. PubMed ID: 12180712
    [No Abstract]   [Full Text] [Related]  

  • 13. The LUNDEX, a new index of drug efficacy in clinical practice: results of a five-year observational study of treatment with infliximab and etanercept among rheumatoid arthritis patients in southern Sweden.
    Kristensen LE; Saxne T; Geborek P
    Arthritis Rheum; 2006 Feb; 54(2):600-6. PubMed ID: 16447237
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Maintaining and optimising anti-TNF therapy.
    Somerville M
    Musculoskeletal Care; 2007 Dec; 5 Suppl 1():1-17. PubMed ID: 18050263
    [No Abstract]   [Full Text] [Related]  

  • 15. Factors influencing response to disease modifying antirheumatic drugs in patients with rheumatoid arthritis.
    Hider SL; Buckley C; Silman AJ; Symmons DP; Bruce IN
    J Rheumatol; 2005 Jan; 32(1):11-16. PubMed ID: 15700388
    [No Abstract]   [Full Text] [Related]  

  • 16. C-reactive protein as a predictor of infliximab treatment outcome in patients with rheumatoid arthritis: defining subtypes of nonresponse and subsequent response to etanercept.
    Buch MH; Seto Y; Bingham SJ; Bejarano V; Bryer D; White J; Emery P
    Arthritis Rheum; 2005 Jan; 52(1):42-8. PubMed ID: 15641046
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A proposed revision to the ACR20: the hybrid measure of American College of Rheumatology response.
    American College of Rheumatology Committee to Reevaluate Improvement Criteria
    Arthritis Rheum; 2007 Mar; 57(2):193-202. PubMed ID: 17330293
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The measure of our measures.
    Harth M; Pope J
    Rheumatology (Oxford); 2004 Dec; 43(12):1465-7. PubMed ID: 15479755
    [No Abstract]   [Full Text] [Related]  

  • 19. Is it time for a European consensus on the pharmacological management of early RA?
    Emery P
    J Rheumatol Suppl; 2002 Nov; 66():1-2. PubMed ID: 12435161
    [No Abstract]   [Full Text] [Related]  

  • 20. Diagnosing early or rheumatoid arthritis. Which is better: expert opinion or evidence?
    Fautrel B
    J Rheumatol; 2009 Nov; 36(11):2375-7. PubMed ID: 19893056
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.